A Randomized Trial of the Effect of a GnRH Analogue Injection on Ghrelin Levels in Girls

What Was Tested

This randomized controlled trial paper looks at Ghrelin.

Ghrelin concentrations decline during puberty by an unclear mechanism.

Who Took Part

The abstract describes 13 girls taking part.

PubMed tags the participants as women only.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and crossover study.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Ghrelin group a baseline to be compared against.

Each person switched between Ghrelin and the comparison at some point, usually with a gap in between.

In this randomized, placebo-controlled, cross-over study, 13 girls with suspected central precocious puberty were included.

Blood was sampled repeatedly for 150 min for the analysis of hormone concentrations.

Oestradiol levels were only measured at baseline.

The protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) was added to the sampling tubes.

What Was Measured

Topics PubMed links to this paper include Ghrelin, Gonadotropin-Releasing Hormone, Estradiol, Protease Inhibitors and Sulfones.

The authors tagged it with the keywords Acylated ghrelin, Central precocious puberty, Desacylated ghrelin and GnRH analogue.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Ghrelin in 13 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Ghrelin compound page, all human trials.